In 69 patients with functional dyspepsia pre-selected by CYP2D6 genotype, escalating low-dose nortriptyline did not improve response vs placebo over 12 weeks (45% vs 58%; OR 0.57, P=0.276); adverse events did not differ.
RCTn = 69
Bosch et al. Tailored Treatment of Functional Dyspepsia With Nortriptyline: A Multicenter, Double-Blind, Placebo-Controlled Trial